基于肿瘤分数的癌症患者预后工具参考早期临床试验。
Tumor fraction-based prognostic tool for cancer patients referred to early phase clinical trials.
发表日期：2024 Oct 07
作者：
Arnaud Bayle, Laila Belcaid, Sophie Cousin, Kilian Trin, Melissa Alame, Etienne Rouleau, Isabelle Soubeyran, Ludovic Lacroix, Laura Blouin, Damien Vasseur, Amandine Crombe, Simone Mathoulin-Pelissier, Jean-Charles Soria, Carine Bellera, Antoine Italiano
来源：
npj Precision Oncology
摘要：
选择患者进行 I 期癌症试验对于确保足够的预期寿命至关重要。体弱的患者更适合姑息治疗，不应该接触效果最小的新药。招募早期死亡高风险的患者可能会危及研究。我们对两项大型精准医学研究的分析使用 ctDNA 中的肿瘤部分来开发预测模型，证明了显着的预测准确性并有助于患者选择。© 2024。作者。
Selecting patients for phase I cancer trials is crucial to ensure a sufficient life expectancy. Frail patients, better suited for palliative care, should not be exposed to new drugs with minimal benefit. Enrolling patients at high risk of early death can jeopardize the study. Our analysis of two large precision medicine studies used tumor fraction from ctDNA to develop a predictive model, demonstrating notable predictive accuracy and aiding in patient selection.© 2024. The Author(s).